Ikris Pharma Network News, Researches and Articles

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Latest Articles

Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE (Vamorolone) in India

Press Releases August 29, 2025 2

Santhera Pharmaceuticals announces the signing of an exclusive agreement...

ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Duvyzat (Givinostat) Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy

Press Releases August 25, 2025 0

ITF Therapeutics affiliate of Italfarmaco, today announced publication of...

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Press Releases August 20, 2025 0

Keros Therapeutics today announced the U.S. Food and Drug...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Treatments December 26, 2024 5

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Research January 5, 2025 7

The results of new gene therapy studies for Duchenne...

Duchenne Muscular Dystrophy: Treatment & Cost

Editorials January 2, 2025 1

The excitement you feel until your child is born...

Ikris Pharma Network

Must Read

RGX-202 Gene Therapy Phase 3 Clinical Trial Begins

Entrada Therapeutics Begins Clinical Trials in Europe for Exon 44 and Exon 45 Skipping Therapies

Wellcome Trust Donates £10 Million to Treat Rare Diseases